resolve over time must be distinguished from those whose deficiency is more permanent. To resolve the above issues, detailed immunological analyses may help to ensure early diagnosis and appropriate treatment. This is imperative because of the high risk of RI, which may cause irreversible organ damage.
The measurement of IgG subclass antibodies (IgGSc) is included in a number of protocols and guidelines for investigating individuals presenting with RIs, lung diseases, and strong suspicion of an antibody deficiency ( Table 1) . These analyses are also helpful in 1) monitoring of transient versus permanent antibody deficiencies, 2) assessing the progression of mild immunodeficiencies into more severe forms, and 3) supporting some treatment decisions (summarized in Table 2 ).
IgGSc deficiency (IgGScD) is clinically and genetically heterogeneous, and may coexist with abnormal expression of more than 1 subclass antibody. Individuals with IgGScD may present with a combination of frequent or severe bacterial infections of the upper and lower respiratory tract, [4] [5] [6] allergic asthma and allergic rhinitis, 7, 8 and autoimmune conditions. In this review, we discuss the clinical situations in which measurement of IgGSc has been reported to be of benefit.
Diagnosis of IgGSc Deficiency
The measurement of IgGSc has been employed as a screening tool for individuals presenting with multiple chronic illnesses or RI ( Table 1) . Some authors have reported measuring IgGSc as a frontline test alongside the measurement of total IgG, IgA, and IgM, [12] [13] [14] [15] but more commonly, the measurement of IgGSc is a second-line test. [16] [17] [18] [19] De Vries 16 has suggested that IgGSc are measured after the measurement of IgG, IgA, and IgM usually if IgG is higher than 4 g/L and alongside the response to vaccination. Ladomenou and Gaspar 19 have suggested that IgGSc concentrations are measured after the assessment of the response to vaccines. Further, IgGSc are useful as part of an evaluation in studying patients with a strong history of infections, normal major isotypes, and normal antibody responses. As discussed below, IgGSc are also recommended as second-line tests in patients with low IgA and should be monitored in IgGScD patients for progression to common variable immunodeficiency (CVID). [20] [21] [22] [23] [24] [25] Whether first or second line, the measurement of IgGSc is an important test that provides a more complete picture of the humoral immune system.
Concentrations of IgGSc are commonly measured using radial immunodiffusion (RID), enzyme-linked immunosorbent assay (ELISA), and the more automated methods of nephelometry and turibidimetry. All methods provide quantitative measurement of the IgGSc concentrations, and all assays provide a good level of sensitivity for detection of low IgGSc concentrations. RID is commonly used if the testing numbers are low, and nephelometric and turbidimetric assays are operated on automated high throughput analysers on which other laboratory assays are run. ELISA may use monoclonal 14, 17 Cunningham Rundles 13 antibodies for detection rather than the polyclonal antibodies used in RID and nephelometric or turbidimetric assays. Time to first result is slower with RID due to incubation times required for antigen-antibody ring formation. For nephelometric and turbidimetric assays, differences exists between manufacturers' assays. [26] [27] [28] [29] Reference ranges for pediatric age groups and adult populations have been developed 30, 31 (Table 3) , as well as some study-specific ranges. 7, 32, 33 
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Mechanism of IgGScD
The human immunoglobulin heavy chain constant region (IGHC) is localized on chromosome 14 and contains 9 functional genes ) are probably the cause of the more pathogenic IgGScD.
There may be prognostic importance in distinguishing between IgGScD caused by gene deletion and that due to immunoregulatory dysfunction as those with the latter may have the higher risk of RI.
IgGScD
IgGScD is one of the most common primary antibody deficiencies (PADs) in both pediatric age groups and adults presenting with RI ( Figure 1 and Table 4) . 43, 44 The most common clinical associations of IgGScD are recurrent encapsulated bacterial and viral respiratory tract infections. 7, [45] [46] [47] The frequency of recurrent pneumonia is significantly higher in IgGScD than that observed in the normal population. Ozkan et al found that the rate of chronic pulmonary damage was 5 times higher in pediatric age groups with IgGScD than those with low IgA. 46 It has been reported that bronchiectasis may already be present in as many as 10% of IgGScD pediatric patients at diagnosis. 43 In a study of 350 adult IgGScD patients, 29% had asthma, 9% had asthma combined with chronic obstructive pulmonary disease (COPD), and 9% had COPD alone. IgG2-and IgG3-are the most common IgGScDs, 7, 43, [45] [46] [47] presumably in part because IgG1 deficiency can closely mirror IgG deficiency. IgG2ScD may be associated with some restricted responses to polysaccharide antigens, and in IgG3ScD, the response to Moraxella catarrhalis, Streptococcus pyogenes, and respiratory syncytial virus infection may be compromised. 49, 50 IgG4 is present at very low concentrations in healthy individuals; thus IgG4 subclass antibodies deficiency (IgG4ScD) may be difficult to diagnose. IgG2ScD is sometimes accompanied by low IgG4 Figure 1) . Along with the clinical presentation, these distinctions may support a reliable diagnosis and treatment regime.
Measurement of IgGSc in Other Antibody Deficiencies
IgGScD in Patients with Low IgA
The majority of patients with low IgA are asymptomatic, but approximately 30% present with infection, eg recurrent viral infections, recurrent otitis media, frequent sinopulmonary infections, or gastrointestinal infections. 63 In addition, low
IgA has been associated with abnormalities of antibody-mediated immunity, such as IgE deficiency, 64 deficient serum IgGSc concentrations, [65] [66] [67] [68] and impaired antibody responses against both protein and polysaccharide antigens. 65, 69, 70 In pediatric age groups presenting with RI, a percentage may have an IgGScD dependent on presentation or type of RI. 21, 55, 71 The additional defective ability to produce normal IgGSc in the background of low IgA may lead to more frequent and more severe infections than those present in patients with normal IgA [20] [21] [22] [23] [24] [25] 68 and is readily observed in patients who present with recurrent bronchitis. 22, 23, 68, [72] [73] [74] [75] [76] When patients with low IgA were grouped according to severity of infection (none, mild, and severe), although the IgA concentrations were not significantly different, mean IgG4 concentrations were lower in the group with mild infections and even lower in the group with severe infections compared to the group with no infections. 65 A higher frequency of infection has also been reported in patients with low IgA and IgG2ScD compared to those with low IgA alone.
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The high rates of infection in patients with low IgA and IgGScD result in decreased lung function, 72 and in particular IgG4ScD correlates with the presentation of bronchiectasis. 78 In some cases, low IgA may evolve into the more severe CVID, and a decrease in IgGSc concentrations may occur before a decrease in total IgG. 20, 78, 79 An algorithm for the testing of IgGSc in individuals with low IgA and utility is shown in Figure 2 .
Finally, and although it is outside the scope of this review, patients with low IgA may present with antibody-mediated autoimmune diseases that reflect a dysregulation of the humoral response. 80 However, little evidence is found in the literature about the association of low IgA and IgGScD with autoimmunity. The evaluations in category A are required to consider a diagnosis of CVID, and to differentiate between those with mild hypogammaglobulinemia of uncertain significance (HGUS) and those whose presentation is more suggestive of CVID ( Figure 3) . Category B details the clinical sequelae from the in vivo failure of the immune system. The determination of recurrent, severe, or unusual infections, particularly in the presence of prophylaxis and treatment, is important, as is excluding infection due to anatomical and functional defects. Category C is the provision of serological and genetic data to support the suggestion of CVID. Many CVID patients have a deficiency of IgG, IgA, and/or IgM, and many have reduced memory B cell subsets. The response to vaccination and concentration of isohemagglutinins are important to assess, as are the serological indications for autoimmunity. Determination of sequence variations in genes known for predisposing one to CVID is important. IgG3ScD may be considered a supportive marker for a defective immune system and should be given similar status to impaired memory B cells. The significance of reduction of any other IgGSc is currently unknown. The final category, D, is the identification of lesions that may be associated with CVID.
Patients with probable CVID must fulfill all criteria in category A, at least 1 from category B, and 3 or more from category C. Category D does not need to be fulfilled, but strengthens the diagnosis of CVID. For patients who do not fulfill category A, one may consider HGUS. Many patients may not 
Measurement of IgGSc Concentrations to Aid the Diagnosis of Specific Antibody Deficiency
It is important to differentiate between isolated IgGScD, SAD, and clinically relevant IgGScD, since the decision process for treatment and management may differ. Individuals with SAD differ from those with isolated IgGScD and clinically relevant IgGScD, since they have normal IgGSc concentrations and always have an impaired response to pneumococcal polysaccharide vaccination. 34, 85 Patients with SAD are predisposed to sinopulmonary bacterial infections, sinusitis, otitis, bronchitis, and pneumonia with pathogens, including Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae, and Streptococcus aureus.
Patients with SAD are managed in a variety of ways, including vaccination with conjugated vaccines, prophylactic antibiotics, and occasionally with antibody replacement therapy. This may differ from the patient management employed for those with isolated IgGScD and certainly for those with clinically relevant IgGScD with respect to antibody replacement. This may be indicative of the differing severity of immune defect among these PIDs (Figure 3) .
Initial treatment of patients with normal IgG but IgGScD or SAD may include antibiotics for the infections and vaccination with the pneumococcal conjugate vaccine. 86 A clear purpose for antibody replacement therapy is reduced levels of serum IgG (<2 g/L) in patients with recurrent bacterial infections, but this may be more difficult to justify in the presence of normal total IgG. The justification may be strengthened, however, for patients with clinically relevant IgGScD, as both IgGSc concentrations and response to vaccination are compromised. Antibody replacement therapy may be indicated in SAD patients, or patients with isolated IgGScD or clinically relevant IgGScD if the patients present with severe and/or RI, 87 even though prophylactic antibiotics have been administered. 48 The decision-making process is governed by clinical presentation, may involve the patients response to treatment, and is a clinician-dependent justification. Measurement of IgGSc is required to support the clinical presentations and the decisions for appropriate treatment.
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Measurement of IgGSc as a Monitoring Tool
Differentiation Between Transient and Persistent Antibody Deficiencies
A challenging issue for the clinician is whether the clinical symptoms presented are the result of a slow maturing immune system or an underlying immune deficiency. Transient hypogammaglobulinemia of infancy (THI) is an antibody deficiency occurring in the first years of life that is characterized by a delay in immunoglobulin production that spontaneously recovers in early infancy. Only those patients whose clinical symptoms have resolved and IgG concentrations have normalized after the age of 4 years have definitive THI. The diagnosis is made a posteriori. 34, 89 Routine measurement and normalisation of IgGSc may differentiate those who have a transient immunodeficiency from those who may have a more persistent polyclonal immunodeficiency. 43, [90] [91] [92] [93] [94] During the follow-up of 24 pediatric age group patients with IgGScD over 40 months, 25% had no further RIs, which correlated with IgGSc normalisation in all individuals tested. 43 Kutukculer and colleagues reported that the IgGSc concentrations in 67% of pediatric age group patients with low IgA and IgGScD and 30% of pediatric age group patients with isolated IgGScD will normalize to age-specific normal concentrations. 95 It has been reported that the mean age for normalization of IgGSc concentrations in pediatric age group patients was between 4 and 6 years of age, 91, 96 and that low IgG2 concentrations may be more challenging to normalize, signifying a more permanent antibody deficiency. 
Influence on Treatment Regimes
Immunoglobulin Replacement Therapy
Current guidelines for the treatment of IgGScD suggest treating any allergic symptoms and support the administration of prophylactic antibiotics. In selected patients, cautious use of polyclonal human IgG may be required. 87, 88 Immunoglobulin prophylaxis reduces the frequency of RI in IgGScD patients 5, 48, [102] [103] [104] [105] and those with low IgA and low Ameratunga and colleagues suggest that the response to vaccination is not an important part of the diagnostic criteria. 83, 84 Goldacker and colleagues supported this further by reporting the response to vaccines in some CVID patients. 109 Measurement of IgGSc may be of interest to determine who requires revaccination or further vaccination, and indeed whether to proceed with polysaccharide or conjugated polysaccharide vaccination.
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Conclusions
The measurement of IgGSc is a frequently requested laboratory test whose extensive clinical indication requires complete understanding.
Individuals are often referred to immunologists for the evaluation of reduced serum immunoglobulins. Normal values of IgG, IgA, and IgM are not always enough to exclude a more serious condition, and alongside the information obtained from measurement of specific antibody production and B lymphocyte populations, measurement of IgGSc can provide a more complete view of the function of the humoral immune system. 19 Measurement of IgGSc may occur as a frontline test alongside the measurement of total immunoglobulins, 12-15 but more commonly, the measurement of IgGSc is a second-line test [16] [17] [18] [19] given alongside or after the response to vaccines. Reference ranges for pediatric age groups and adult populations have been developed to aid identification of low concentrations, and a minimum of 2 measurements are required to confirm a diagnosis of IgGScD. Several methods are available for quantitation of the IgGSc concentrations, and several differences exist between manufacturers' assays within a certain technique. This may influence quantitation, and therefore care must be taken to ensure serial monitoring for patients is performed within a single laboratory rather than across multiple laboratories to ensure a single technique is used.
Measurement of IgGSc can support the diagnosis of CVID and aid in the risk stratification of individuals with low IgA. The utility of the IgGSc is most prominent when combined with the response to vaccination. The discrimination between isolated IgGScD, SAD, and clinically relevant IgGScD is particularly important since this may influence treatments. There is clear utility for the measurement of IgGSc as a monitoring tool. The use alongside the measurement of total IgG may further aid differentiation between THI and a more permanent PAD. Prognostic information may be obtained by defining the cause of the deficiency.
IgGScD may influence frequency and severity of infection. The measurement of IgGSc should always be considered within a panel of other tests. In PADs the measurement of IgGSc and the response to vaccination provides a comprehensive window into the function of the immune system. LM
